

Press Briefing Schedule At-a-Glance

All on-site Press Briefings are located in McCormick Place, Lakeside Building E353a

Wednesday, May 15	Saturday, June 1	Sunday, June 2	Monday, June 3
<p>Presscast Briefing</p> <p>Press Briefing Time: 12:00-1:30 p.m. ET <i>Virtual event conducted via live teleconference and webinar</i></p> <p>Embargo Lifts: 5:00 p.m. ET</p> <p>Abstract 520: <i>Low-fat dietary pattern and long-term breast cancer incidence and mortality: The Women's Health Initiative randomized clinical trial.</i></p> <p>Abstract 10009: <i>Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.</i></p> <p>Abstract 10011: <i>Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial.</i></p> <p>Abstract 4006: <i>Optimizing chemotherapy for frail and elderly patients with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial.</i></p> <p>Abstract 8001: <i>E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high risk smoldering multiple myeloma.</i></p>	<p>News of the Day</p> <p>Press Briefing Time: 8:00-9:00 a.m. CT</p> <p>Embargo Lifts: 6:30 a.m. CT</p> <p>Announcement: Minimal Common Oncology Data Elements (mCODE™), a collaboration between ASCO®, the MITRE Corporation, and the Alliance for Clinical Trials in Oncology Foundation</p> <p>Abstract LBA1008: <i>Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.</i></p> <p>Abstract LBA9015: <i>Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.</i></p> <p>Abstract LBA4007: <i>Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase 3 KEYNOTE-062 study.</i></p>	<p>News of the Day</p> <p>Press Briefing Time: 8:00-9:00 a.m. CT</p> <p>Embargo Lifts: 6:30 a.m. CT</p> <p>*Abstract LBA5563: <i>Impact of the Affordable Care Act on early-stage diagnosis and treatment for women with ovarian cancer.</i></p> <p>Abstract LBA107: <i>Insurance status and survival of multiple myeloma patients.</i></p> <p>Abstract LBA1: <i>Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment.</i></p> <p>Abstract LBA2: <i>Overall survival (OS) results of a phase III randomized trial of standard of care therapy with or without enzalutamide for metastatic hormone sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international co-operative group trial.</i></p> <p>Abstract LBA4: <i>Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.</i></p> <p>*Based on scientific presentation, embargo on this abstract lifts at 6:30 a.m. CT, Sat. June 1</p>	<p>News of the Day</p> <p>Press Briefing Time: 8:00-9:00 a.m. CT</p> <p>Embargo Lifts: 6:30 a.m. CT</p> <p>Announcement: FDA Oncology Center of Excellence launches Project Facilitate for oncology Expanded Access requests</p> <p>Abstract LBA10502: <i>Survey of sexual harassment and gender disparities among gynecologic oncologists.</i></p> <p>Abstract LBA3516: <i>Long term survival after laparoscopic versus open resection for colorectal liver metastases.</i></p> <p>Abstract LBA108: <i>Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis.</i></p> <p>Abstract LBA4505: <i>EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.</i></p>